For example, CTLA-4 expression increased in tumors after nivolumab, supporting the rationale for combining anti-CTLA-4 agents with anti-PD-1 agents in the neoadjuvant setting—the first dual ICI combination approved for the frontline treatment of metastatic ccRCC. Here, PDCD1 is linked to nonpapillary renal cell carcinoma.